Cite

HARVARD Citation

    Caplin, M. et al. (2016). Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study. Endocrine-related cancer. 23 (3), pp. 191-199. [Online]. 
  
Back to record